Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Gains from Sales and Divestitures (2017 - 2024)

Aethlon Medical (AEMD) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $76943.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $76943.0, compared with a TTM value of $76943.0 through Dec 2024, changed N/A, and an annual FY2024 reading of $34378.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $76943.0 for Q4 2024 at Aethlon Medical, up from $27602.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $76943.0 in Q4 2024 and bottomed at $27602.0 in Q2 2024.